AR035567A1 - Composiciones que comprenden bloqueadores de transferencia de celula renal l-dopa para el tratamiento de la enfermedad de parkinson - Google Patents
Composiciones que comprenden bloqueadores de transferencia de celula renal l-dopa para el tratamiento de la enfermedad de parkinsonInfo
- Publication number
- AR035567A1 AR035567A1 ARP010101199A ARP010101199A AR035567A1 AR 035567 A1 AR035567 A1 AR 035567A1 AR P010101199 A ARP010101199 A AR P010101199A AR P010101199 A ARP010101199 A AR P010101199A AR 035567 A1 AR035567 A1 AR 035567A1
- Authority
- AR
- Argentina
- Prior art keywords
- dopa
- renal cell
- compound
- parkinson
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 5
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229930003935 flavonoid Natural products 0.000 abstract 2
- 235000017173 flavonoids Nutrition 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 abstract 2
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical class C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 abstract 2
- 102000004031 Carboxy-Lyases Human genes 0.000 abstract 1
- 108090000489 Carboxy-Lyases Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 abstract 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000911 benserazide Drugs 0.000 abstract 1
- 150000001562 benzopyrans Chemical class 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 229960003337 entacapone Drugs 0.000 abstract 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 abstract 1
- -1 flavonoid compound Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940016667 resveratrol Drugs 0.000 abstract 1
- 235000021283 resveratrol Nutrition 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229960004603 tolcapone Drugs 0.000 abstract 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica para el tratamiento de la enfermedad de Parkinson comprende L-DOPA y al menos un compuesto capaz de bloquear la ruta de transferencia de salida de célula renal L-DOPA; dicho compuesto de bloqueo se elige de (a) un derivado de benzopirano de fenilo flavonoide; (b) un derivado de trans-estilbeno; o (c) floretina [3-(4-hidroxifenil)-1-(2,4,6-trihidroxifenil)-1-propanona]. La composición puede comprender también un inhibidor de la enzima aminoácido decarboxilasa (AADC), tal como carbidopa o benserazida, y/o un inhibidor de la enzima catecol-O-transferasa (COMT), tal como entacapona o tolcapona. La composición se administra preferentemente en forma sólida y la L-DOPA se puede administrar simultáneamente o consecutivamente con el compuesto de bloqueo de transferencia de salida de célula renal L-DOPA. Reivindicación 3: Una composición de acuerdo con la reivindicación 2, caracterizado porque el compuesto flavonoide presenta la fórmula general (1), donde los grupos X son iguales o diferentes y se seleccionan de H y OH, los grupos y son iguales o diferentes y se seleccionan de H y OR donde R representa H, CH3 y CH2-Ph, incluyendo los derivados 3-C6H5(Y4) correspondientes. Reivindicación 4: Una composición de acuerdo con la reivindicación 1, caracterizado porque el derivado de trans-estilbeno presenta la fórmula general (2) caracterizado porque los grupos X son iguales o diferentes y son H u OH. Reivindicación 6: Una composición de acuerdo con cualquiera de las reivindicaciones 1, 4 o 5, caracterizado porque el compuesto de bloqueo es resveratrol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0006063A GB2348371B (en) | 2000-03-14 | 2000-03-14 | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035567A1 true AR035567A1 (es) | 2004-06-16 |
Family
ID=9887552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101199A AR035567A1 (es) | 2000-03-14 | 2001-03-15 | Composiciones que comprenden bloqueadores de transferencia de celula renal l-dopa para el tratamiento de la enfermedad de parkinson |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040242503A1 (es) |
| EP (1) | EP1267853B1 (es) |
| JP (1) | JP3677002B2 (es) |
| KR (1) | KR100738746B1 (es) |
| CN (1) | CN1262269C (es) |
| AR (1) | AR035567A1 (es) |
| AT (1) | ATE275397T1 (es) |
| AU (1) | AU781280B2 (es) |
| BR (1) | BR0109220A (es) |
| CA (1) | CA2402712C (es) |
| CZ (1) | CZ297123B6 (es) |
| DE (1) | DE60105401T2 (es) |
| DK (1) | DK1267853T3 (es) |
| ES (1) | ES2228858T3 (es) |
| GB (1) | GB2348371B (es) |
| HU (1) | HUP0300130A3 (es) |
| MX (1) | MXPA02009043A (es) |
| PL (1) | PL359327A1 (es) |
| PT (1) | PT1267853E (es) |
| RU (1) | RU2266111C2 (es) |
| SI (1) | SI1267853T1 (es) |
| TR (1) | TR200402661T4 (es) |
| WO (1) | WO2001068065A2 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| US7381772B2 (en) * | 2003-12-12 | 2008-06-03 | E. I. Du Pont De Nemours And Company | Toughened poly(lactic acid) compositions |
| ES2390126T3 (es) * | 2004-06-04 | 2012-11-06 | Xenoport, Inc. | Derivados de levodopa, y composicones y usos de la misma |
| EP1781094B1 (en) * | 2004-07-07 | 2016-04-27 | Kampavata AB | Transgenic non-human animal for use in research models for studying parkinson's disease |
| RU2431634C2 (ru) * | 2005-03-11 | 2011-10-20 | Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин | Соединения флавоноидов и их применение |
| GB0505756D0 (en) * | 2005-03-21 | 2005-04-27 | Mars Uk Ltd | Method |
| US20090012170A1 (en) * | 2005-09-21 | 2009-01-08 | Helena Nissinen | Treatment of symptoms of motor dysfunction |
| EP1957109A2 (en) * | 2005-12-02 | 2008-08-20 | Sirtris Pharmaceuticals, Inc. | Modulators of cdc2-like kinases (clks) and methods of use thereof |
| TWI403493B (zh) | 2005-12-05 | 2013-08-01 | Xenoport Inc | 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途 |
| US7829592B2 (en) | 2006-12-21 | 2010-11-09 | Xenoport, Inc. | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| TW200843732A (en) | 2006-12-21 | 2008-11-16 | Xenoport Inc | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| AU2008257437A1 (en) * | 2007-02-14 | 2008-12-04 | Mars, Incorporated | Neurogenic compounds |
| BRPI0801239A2 (pt) * | 2008-04-01 | 2009-11-17 | Ache Lab Farmaceuticos Sa | uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase |
| US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| EP2349973A2 (en) | 2008-10-20 | 2011-08-03 | XenoPort, Inc. | Methods of synthesizing a levodopa ester prodrug |
| US20100158829A1 (en) * | 2008-12-24 | 2010-06-24 | Conopco, Inc., D/B/A Unilever | Method and Composition for Color Modulation |
| CN105902535A (zh) * | 2009-04-13 | 2016-08-31 | 中国医学科学院药物研究所 | 黄芩素在制备预防和治疗帕金森病药物中的应用 |
| RU2537137C2 (ru) | 2009-11-09 | 2014-12-27 | Ксенопорт, Инк. | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения |
| CN101797243B (zh) * | 2010-03-23 | 2012-01-18 | 广东药学院 | 一种含有左旋多巴和冰片的组合物及其应用 |
| KR101327936B1 (ko) * | 2011-07-06 | 2013-11-13 | 한국식품연구원 | 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물 |
| CN102755312A (zh) * | 2012-07-16 | 2012-10-31 | 中国科学院大连化学物理研究所 | 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用 |
| GB201302755D0 (en) | 2013-02-15 | 2013-04-03 | Mars Inc | Horse supplement |
| CN103211832A (zh) * | 2013-04-24 | 2013-07-24 | 无锡艾德美特生物科技有限公司 | 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途 |
| CN104116730A (zh) * | 2013-04-26 | 2014-10-29 | 中国科学院大连化学物理研究所 | 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用 |
| KR101583399B1 (ko) * | 2013-10-22 | 2016-01-08 | 충북대학교 산학협력단 | 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물 |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| KR102681552B1 (ko) * | 2016-09-27 | 2024-07-04 | (주)아모레퍼시픽 | 소장 상피세포에서의 카테킨 흡수 증진제 |
| CN111329853A (zh) * | 2020-04-21 | 2020-06-26 | 遵义医科大学 | 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物 |
| CN116908319A (zh) * | 2023-05-31 | 2023-10-20 | 苏州和合医学检验有限公司 | 一种检测血液中苄丝肼浓度的方法 |
| CN119192117B (zh) * | 2024-10-31 | 2025-09-26 | 贵州医科大学 | 一种从马尾松松塔内分离出的黄酮类化合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4190672A (en) * | 1978-09-01 | 1980-02-26 | Stanley Fahn | Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone |
| JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | パ−キンソン病治療剤 |
| JPS6450877A (en) * | 1987-08-20 | 1989-02-27 | Ichimaru Pharcos Inc | Oxygen radical catching and removing agent |
| JPH035423A (ja) * | 1989-06-01 | 1991-01-11 | Ichimaru Pharcos Co Ltd | フラボノイド含有過酸化脂質生成抑制剤 |
| US5702752A (en) * | 1996-03-13 | 1997-12-30 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
| JPH09241637A (ja) * | 1996-03-14 | 1997-09-16 | Chugai Pharmaceut Co Ltd | 活性酸素ラジカル除去用組成物およびその方法 |
| GB9702310D0 (en) * | 1997-02-05 | 1997-03-26 | Univ Hertfordshire | Invention |
| US6537969B1 (en) * | 1997-10-24 | 2003-03-25 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| JPH11323326A (ja) * | 1998-02-06 | 1999-11-26 | Nagaoka Koryo Kk | 活性酸素消去剤、皮膚保全剤および変色防止剤 |
| FR2787319B1 (fr) * | 1998-12-22 | 2002-06-14 | Oreal | Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| CN101822676A (zh) * | 2002-01-28 | 2010-09-08 | 协和发酵麒麟株式会社 | 治疗运动疾病患者的方法 |
-
2000
- 2000-03-14 GB GB0006063A patent/GB2348371B/en not_active Expired - Fee Related
-
2001
- 2001-03-13 ES ES01931528T patent/ES2228858T3/es not_active Expired - Lifetime
- 2001-03-13 US US10/221,496 patent/US20040242503A1/en not_active Abandoned
- 2001-03-13 PT PT01931528T patent/PT1267853E/pt unknown
- 2001-03-13 JP JP2001566629A patent/JP3677002B2/ja not_active Expired - Fee Related
- 2001-03-13 CZ CZ20023348A patent/CZ297123B6/cs not_active IP Right Cessation
- 2001-03-13 EP EP01931528A patent/EP1267853B1/en not_active Expired - Lifetime
- 2001-03-13 AT AT01931528T patent/ATE275397T1/de not_active IP Right Cessation
- 2001-03-13 HU HU0300130A patent/HUP0300130A3/hu unknown
- 2001-03-13 BR BR0109220-0A patent/BR0109220A/pt not_active Application Discontinuation
- 2001-03-13 TR TR2004/02661T patent/TR200402661T4/xx unknown
- 2001-03-13 SI SI200130247T patent/SI1267853T1/xx unknown
- 2001-03-13 CA CA002402712A patent/CA2402712C/en not_active Expired - Fee Related
- 2001-03-13 PL PL01359327A patent/PL359327A1/xx not_active Application Discontinuation
- 2001-03-13 RU RU2002127782/15A patent/RU2266111C2/ru not_active IP Right Cessation
- 2001-03-13 KR KR1020027012049A patent/KR100738746B1/ko not_active Expired - Fee Related
- 2001-03-13 MX MXPA02009043A patent/MXPA02009043A/es active IP Right Grant
- 2001-03-13 DE DE60105401T patent/DE60105401T2/de not_active Expired - Fee Related
- 2001-03-13 AU AU58283/01A patent/AU781280B2/en not_active Ceased
- 2001-03-13 DK DK01931528T patent/DK1267853T3/da active
- 2001-03-13 CN CNB018093752A patent/CN1262269C/zh not_active Expired - Fee Related
- 2001-03-13 WO PCT/EP2001/002896 patent/WO2001068065A2/en not_active Ceased
- 2001-03-15 AR ARP010101199A patent/AR035567A1/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035567A1 (es) | Composiciones que comprenden bloqueadores de transferencia de celula renal l-dopa para el tratamiento de la enfermedad de parkinson | |
| AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
| BRPI0311275A2 (pt) | "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas" | |
| BR0313162A (pt) | Composto, processo para preparar o mesmo, e, composição farmacêutica | |
| DK1112005T4 (da) | Antioxiderende præparat, som omfatter acetyl-L-carnitin og alfa-lipoinsyre | |
| BRPI0409133A (pt) | formulações farmacêuticas contendo metilnaltrexona | |
| ECSP034896A (es) | Derivados aromaticos de acidos dicarboxilicos | |
| BRPI0416692A (pt) | inibidores heterocìclicos de mek e métodos de emprego destes | |
| UY26058A1 (es) | Compuestos utiles como antiinflamatorios ley 17.164 art. 127 | |
| NO20013675L (no) | 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer | |
| HRP20080297T3 (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol | |
| AR029456A1 (es) | Forma triturada | |
| GT200600520A (es) | Agentes antibacterianos | |
| MXPA05002652A (es) | Composicion oralmente administrable para mejorar la calidad de la piel. | |
| UY27338A1 (es) | Nuevos derivados de ácido sulfónico | |
| DK1638582T3 (da) | Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after | |
| ES2530579T3 (es) | Análogos de propofol, procedimiento para su preparación, y procedimientos de uso | |
| BR0013582A (pt) | Agonistas retinóides seletivos para rar | |
| AR045912A1 (es) | Composiciones farmaceuticas que contienen derivados de azetidina | |
| AR033596A1 (es) | Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno | |
| AR019737A4 (es) | Composicion antioxidante, citostatica y de energia sostenida que mejora la utilizacion metabolica de glucosa | |
| AR023219A1 (es) | Combinacion de inhibidor(es) de no-sintasa y antioxidante(s) metabolico(s) | |
| AR026451A1 (es) | Compuestos heterociclicos sililados | |
| NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
| ES2195266T3 (es) | Derivados beta,beta-sustituidos de 9-desoxo-9a-n-etenil-9a-aza-9a-homoeritromicina a. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |